CagriSema (Semaglutide + Cagrilintide)
Also known as: CagriSema 1:1 Blend, Semaglutide + Cagrilintide Stack, Dual GLP-1 + Amylin Agonist
Studied in published research — not a medical recommendation. Primary protocol (REDEFINE-1 1:1 Weekly Titration Protocol): 0.25 mg / 0.25 mg starting dose -> titrate every 4 weeks up to 2.4 mg / 2.4 mg max, Once weekly.
Once weekly
Research-reported range; the linked study used a different dose or units. Always start at 0.25mg/0.25mg; escalating Cagrilintide too fast causes pronounced early satiety and fatigue
Subcutaneous injection
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 20 doses in the vial at the low end.
Save CagriSema (Semaglutide + Cagrilintide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a GLP-1 Agonist?
A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.
Bottom Line Up Front
CagriSema combines Semaglutide (GLP-1 agonist) with Cagrilintide (long-acting amylin/calcitonin dual receptor agonist). Clinical trials and pre-mixed vials use a 1:1 ratio (2.5mg/2.5mg or 5mg/5mg titrated from 0.25/0.25 mg weekly), while many independent researchers prefer separate vials (3:1 to 5:1 ratio) to titrate Cagrilintide more slowly (0.25–0.5 mg/week).
Published preclinical & translational clinical protocols
Large multi-year outcomes in healthy non-clinical cohorts
None
3 (0 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. CagriSema (Semaglutide + Cagrilintide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
CagriSema is a next-generation metabolic combination pairing Semaglutide (GLP-1R agonist) with Cagrilintide (a lipidated long-acting DACRA targeting amylin AMY1–3 and calcitonin receptors in the area postrema). Because GLP-1 and amylin act on distinct, non-overlapping satiety centers in the hypothalamus and brainstem, combining them overcomes GLP-1 monotherapy plateaus and produced 22.7% mean weight reduction in the 68-week Phase 3 REDEFINE-1 trial.
Mechanisms of Action
- Semaglutide activates hypothalamic and pancreatic GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress appetite
- Cagrilintide activates amylin (AMY1R/AMY3R) and calcitonin receptors in the area postrema and nucleus tractus solitarius
- Dual-pathway synergy slows gastric emptying, blunts postprandial glucagon, and restores leptin sensitivity during caloric deficit
Common Ratios, Vial Formats & Dosing Breakdown
Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.
1:1 Fixed Clinical Ratio (REDEFINE Trial / Pre-Mixed Vial)
2.5mg Semaglutide / 2.5mg Cagrilintide (5mg total) or 5mg / 5mg (10mg total)
Start 0.25mg + 0.25mg once weekly; titrate every 4 weeks (0.5/0.5 -> 1.0/1.0 -> 1.7/1.7 -> 2.4/2.4 mg)
Why this ratio: Matches Novo Nordisk's fixed-dose co-formulation. With a 5mg/5mg vial + 2mL BAC water, 10 units = 250 mcg of each.
Separate-Vial Asymmetric Layering (Low-Nausea Protocol)
5mg Semaglutide vial + 5mg Cagrilintide vial (separate)
1.0–2.0 mg Semaglutide weekly + 0.25–0.5 mg Cagrilintide staggered 3.5 days later
Why this ratio: Preferred by many users because Cagrilintide provides strong satiety at just 0.25–0.5 mg/week without requiring a full 1:1 match.
Research Protocols
Summaries of published research. For educational purposes only.
Metabolic, Hepatic & Incretin Safety Biomarker Panel (CagriSema (Semaglutide + Cagrilintide))
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Never mix Semaglutide and Cagrilintide in the same syringe for long-term storage unless buffered appropriately (commercial CagriSema uses a dual-chamber pen due to pH differences)
- •Monitor for GI adverse events (nausea, delayed gastric emptying); contraindicated in MTC/MEN2 history
Where to get CagriSema (Semaglutide + Cagrilintide), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.